, pharmaceutical and biotechnology industries. His previous experience includes Bayer Pharmaceuticals, where he last served as Vice President of Business Development for Biotechnology. Dr. Cochran also served as CEO and executive director of the Blanchette Rockefeller Neurosciences Institute; and was a senior member of MDS Capital, a Toronto-based Healthcare venture capital group, where he was responsible for their San Francisco venture business and several MDS invested companies. Dr. Cochran holds a doctorate in microbiology and immunology from Queen's University, Kingston, Ontario; a master's in microbiology from the University of Guelph
, Ontario, and a bachelor's degree from the University of Toronto
Microbix is on the threshold of significant growth powered by the following expected developments within the year:
- Become cash-flow positive.
- Begin construction on the first phase of the Microbix/Hunan JV
influenza manufacturing facility in China.
- Receive its Canadian Urokinase license from Health Canada.
- Launch KINLYTIC in Canada and other markets.
- Announce new partnerships in its SST program.
Microbix has the people, the products and the pipeline to deliver on the goals of its business strategy and significantly build shareholder value. The Company thanks its employees for their efforts, its partners for their interest and its shareholders for their continued support.
Microbix specializes in the development of biological technologies and commercializing them through global partners. The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Established in 1988, Microbix is headquartered in Toronto.
This press release contains forward-looking statements, which are subject to risks and un
Page: 1 2 3 4 5 6 7 Related biology technology :1
|SOURCE Microbix Biosystems Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase2
. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 20093
. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline4
. Microbix Announces A New Technology Platform For The SST Project5
. Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half 096
. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market7
. Microbix Sales Grow 22% For Nine Months8
. Microbix And Hunan Biopharmaceutical To Build Asias Largest Influenza Vaccine Facility9
. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market10
. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute11
. Primera Biosystems Raises $21 Million in Series B Private Round